|
🐜
|
CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition
36 auth.
D. Gallo,
Jordan T. F. Young,
Jimmy Fourtounis,
Giovanni Martino,
Alejandro Álvarez-Quilón,
Cynthia Bernier,
Nicole M. Duffy,
R. Papp,
A. Roulston,
R. Stocco,
Janek Szychowski,
A. Veloso,
Hunain Alam,
P. Baruah,
A. Fortin,
...
Julian Bowlan,
N. Chaudhary,
Jessica Desjardins,
Evelyne Dietrich,
S. Fournier,
Chloe Fugère-Desjardins,
T. Goullet de Rugy,
M. Leclaire,
Bingcan Liu,
V. Bhaskaran,
Y. Mamane,
Henrique Melo,
O. Nicolas,
A. Singhania,
R. Szilard,
J. Tkáč,
S. Yin,
S. Morris,
M. Zinda,
C. G. Marshall,
D. Durocher
|
6 |
2021 |
6
🐜
|
|
🐜
|
RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
29 auth.
A. Roulston,
Michal Zimmermann,
R. Papp,
A. Skeldon,
Charles Pellerin,
Émilie Dumas-Bérubé,
V. Dumais,
Stéphane Dorich,
L. Fader,
S. Fournier,
Li Li,
Marie-Eve Leclaire,
S. Yin,
Amandine Chefson,
Hunain Alam,
...
William W. Yang,
Chloe Fugère-Desjardins,
Sabrina Vignini-Hammond,
K. Skorey,
Amina Mulani,
V. Rimkunas,
A. Veloso,
M. Hamel,
R. Stocco,
Y. Mamane,
Zuomei Li,
Jordan T. F. Young,
M. Zinda,
W. Black
|
5 |
2021 |
5
🐜
|
|
🐜
|
Guiding ATR and PARP inhibitor combinations with chemogenomic screens
12 auth.
Michal Zimmermann,
Cynthia Bernier,
B. Kaiser,
S. Fournier,
Li Li,
Jessica Desjardins,
...
A. Skeldon,
V. Rimkunas,
A. Veloso,
Jordan T. F. Young,
A. Roulston,
M. Zinda
|
4 |
2021 |
4
🐜
|
|
🐜
|
Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500).
37 auth.
W. Black,
Abbas Abdoli,
Xiuli An,
Anick Auger,
Patrick Beaulieu,
Michel Bernatchez,
Cathy Caron,
Amandine Chefson,
Sheldon Crane,
Mohamed Diallo,
Stéphane Dorich,
Lee D Fader,
Gino B Ferraro,
S. Fournier,
Qi Gao,
...
Yelena Ginzburg,
M. Hamel,
Yongshuai Han,
Paul Jones,
Stéphanie Lanoix,
Cyrus M Lacbay,
Marie-Eve Leclaire,
Maayan Levy,
Y. Mamane,
Amina Mulani,
R. Papp,
Charles Pellerin,
Audrey Picard,
Alexander M. Skeldon,
K. Skorey,
R. Stocco,
Miguel St-Onge,
Jean-François Truchon,
V. Truong,
Michal Zimmermann,
M. Zinda,
A. Roulston
|
2 |
2024 |
2
🐜
|
|
🐜
|
ATR inhibitor camonsertib (RP-3500) suppresses early-stage erythroblasts by mediating ferroptosis
14 auth.
M. Levy,
G. Ferraro,
M. Planoutene,
L. Li,
Y. Han,
L. Varicchio,
S. Fournier,
X. An,
S. Morris,
M. Koehler,
...
R. Hoffman,
A. Fretland,
A. Roulston,
Y. Ginzburg
|
1 |
2022 |
1
🐜
|
|
🐜
|
CDK12 loss leads to replication stress and sensitivity to combinations of the ATR inhibitor camonsertib (RP-3500) with PARP inhibitors
14 auth.
J. Setton,
D. Gallo,
D. Głodzik,
B. Kaiser,
S. Braverman,
T. Ubhi,
S. Fournier,
P. Selenica,
N. Laterreur,
A. Roulston,
...
G. Brown,
S. Morris,
J. Reis-Filho,
M. Zimmermann
|
0 |
2022 |
0
🐜
|
|
🐜
|
The PKMYT1 inhibitor RP-6306 has synergistic efficacy with carboplatin in CCNE1 amplified tumor models
11 auth.
J. Fourtounis,
D. Gallo,
A. Roulston,
R. Stocco,
G. Martino,
S. Fournier,
...
E. Aguado,
R. Kryczka,
V. Bhaskaran,
S. Morris,
C. G. Marshall
|
0 |
2022 |
0
🐜
|
